No Data
No Data
No Data
No Data
No Data
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment
Sirnaomics (HKG:2257) received guidance from the US Food and Drug Administration for the drugmaker's phase 2/3 and phase 3 clinical studies of STP705 for treating squamous cell carcinoma in situ. The
MT NewswiresApr 17 07:34 ET
Cash flow is about to run out, and Shengnuo Pharmaceutical-B (02257) is surging only to “trick people”?
The stock price dropped 90% within a year, and the majority shareholders were forced to close their positions last month. At this juncture, the stock price suddenly surged more than 20%, which is probably not a good thing for Shengnuo Pharmaceutical-B (02257). On April 17, Shengnuo Pharmaceutical's stock price opened higher in early trading, reaching a maximum increase of 37.87%. According to the news, Shengnuo Pharmaceutical announced on the same day that the company has obtained a written response from the US FDA's Class C meeting on the requirements of its core product STP705. The company has initiated the required preclinical studies in accordance with FDA guidance recommendations. According to the Zhitong Finance App, the purpose of the Class C conference mentioned above was to obtain F
Zhitong FinanceApr 17 04:33 ET
Shengnuo Pharmaceutical-B (02257): Further development of STP705 for sirnaomics to treat squamous cell carcinoma in situ obtained specific guidance from the FDA
Shengnuo Pharmaceutical-B (02257) issued an announcement. The company has obtained information from the US Food and Drug Administration (FDA)...
Zhitong FinanceApr 16 10:31 ET
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257) fell more than 11% in the afternoon to a record low. The company's cash flow is urgent, and no products have been commercialized
The Zhitong Finance App learned that Shengnuo Pharmaceutical-B (02257) fell more than 11% in the afternoon to a new low. Recently, the stock price has continued to decline, with the biggest drop of more than 93% from its all-time high. As of press release, it fell 11.07% to HK$6.43, with a turnover of HK$16.9093 million. According to the news, Shengnuo Pharmaceutical's 2023 financial report shows that the company obtained additional revenue of US$1,414,000 during the period, a year-on-year decrease of 33.11%; shareholders should have accounted for a loss of US$786.91 million, a decrease of 10.88% year-on-year. Furthermore, according to Wind data, the company's cash and cash equivalents ranged from 2
Zhitong FinanceApr 12 01:58 ET
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257) fell nearly 5%, directors' salary increases raised questions in the market, and the company's cash flow was urgent
Shengnuo Pharmaceutical-B (02257) fell nearly 5%. As of press release, it was down 4.79% to HK$7.55, with a turnover of HK$4.724,200.
Zhitong FinanceApr 10 22:15 ET
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257) rose more than 8% in early trading, CEO says there will be no risk of forced sale of the shares held
The Zhitong Finance App learned that Shengnuo Pharmaceutical-B (02257) rose more than 8% in early trading. As of press release, it had risen 6.22% to HK$8.54, with a turnover of HK$8.3984 million. According to the news, Lu Yang, founder and CEO of Shengnuo Pharmaceuticals, said in an investor conference call in response to investors' questions that his shares will no longer be at risk of being forcibly sold. Shengnuo Pharmaceutical previously announced that the 1,560,000 company shares held by Lu Yang, accounting for 1.78% of the total number of issued shares, were forcibly sold on March 7, 2024. In addition, Shengnuo Pharmaceuticals recently announced annual results for the group's period
Zhitong FinanceApr 2 21:48 ET
No Data
No Data